EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Articles|April 25, 2012
Skin Disorders Video 2: Seborrheic Dermatitis
Red face. Roseacea? Lupus? Sunburn? No, it's seborrheic dermatitis. Here's how to tell.
Advertisement
Ted Rosen, MD, Professor of Dermatology at Baylor College of Medicine, offers bite-size pieces of useful clinical information on the “Top 10” skin disorders you see in your daily practice.
Segment 2: Seborrheic Dermatitis
For more webinar videos,
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
2
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
3
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
4
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
5